USING GENETICALLY ENGINEERED BIOLOGICAL DRUGS (GEBD) IN TREATMENT OF SEVERE FORMS OF JUVENILE CHRONIC ARTHRITIS
Journal: Journal of the Grodno State Medical University (Vol.52, No. 4)Publication Date: 2016-01-27
Authors : Batyan G.M.; Kozharskaya L.G.; Zenevich G.I.; Klechan S.I.;
Page : 76-79
Keywords : genetically engineered biological drugs; joint diseases; remission; cytokines;
Abstract
In recent years significant progress has been achieved in juvenile chronic arthritis treatment due to the use of genetically engineered biological drugs. The results of the use of infliximab, adalimumab, tocilizumab, rituximab in children with severe forms of joint diseases aged from 1 to 17 years are given in the article. It has been established that the use of biological drugs significantly reduces the inflammatory process activity, contributes to remission and improves the prognosis of the disease.
Other Latest Articles
- FUNCTIONAL STATUS OF ADRENAL GLANDS IN PATIENTS WITH PSORIASIS
- CLINICAL EVALUATION OF ORTHOPEDIC TREATMENT OF DENTITION DEFECTS OF THE LOWER JAW WITH SINGLE SAVED TEETH
- PHYSIOLOGICAL PORTRAIT OF A STUDENT OF GRODNO STATE MEDICAL UNIVERSITY
- CHANGES OF RATES AND TERMS OF PUBERTY IN URBAN SCHOOLCHILDREN EXAMINED IN 1982-1983 AND 2010-2012 YEARS
- SOME FEATURES OF SICKLY CHILDREN ENDOCRINE, IMMUNE, LIPID TRANSPORT SYSTEMS DURING ACUTE RESPIRATORY INFECTIONS
Last modified: 2016-01-29 20:57:47